These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. Wolpert C; Schimpf R; Giustetto C; Antzelevitch C; Cordeiro J; Dumaine R; Brugada R; Hong K; Bauersfeld U; Gaita F; Borggrefe M J Cardiovasc Electrophysiol; 2005 Jan; 16(1):54-8. PubMed ID: 15673388 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of quinidine in high-risk patients with Brugada syndrome. Belhassen B; Glick A; Viskin S Circulation; 2004 Sep; 110(13):1731-7. PubMed ID: 15381640 [TBL] [Abstract][Full Text] [Related]
26. Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome. McPate MJ; Duncan RS; Witchel HJ; Hancox JC J Mol Cell Cardiol; 2006 Sep; 41(3):563-6. PubMed ID: 16842817 [TBL] [Abstract][Full Text] [Related]
27. Short QT Syndrome: a familial cause of sudden death. Gaita F; Giustetto C; Bianchi F; Wolpert C; Schimpf R; Riccardi R; Grossi S; Richiardi E; Borggrefe M Circulation; 2003 Aug; 108(8):965-70. PubMed ID: 12925462 [TBL] [Abstract][Full Text] [Related]
28. Multiple clinical profiles of families with the short QT syndrome. Akdis D; Saguner AM; Medeiros-Domingo A; Schaller A; Balmer C; Steffel J; Brunckhorst C; Duru F Europace; 2018 Jun; 20(FI1):f113-f121. PubMed ID: 29016797 [TBL] [Abstract][Full Text] [Related]
29. Long-term follow-up of a pediatric cohort with short QT syndrome. Villafañe J; Atallah J; Gollob MH; Maury P; Wolpert C; Gebauer R; Watanabe H; Horie M; Anttonen O; Kannankeril P; Faulknier B; Bleiz J; Makiyama T; Shimizu W; Hamilton RM; Young ML J Am Coll Cardiol; 2013 Mar; 61(11):1183-91. PubMed ID: 23375927 [TBL] [Abstract][Full Text] [Related]
30. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. Hong K; Bjerregaard P; Gussak I; Brugada R J Cardiovasc Electrophysiol; 2005 Apr; 16(4):394-6. PubMed ID: 15828882 [TBL] [Abstract][Full Text] [Related]
32. Arrhythmogenic hereditary syndromes: Brugada Syndrome, long QT syndrome, short QT syndrome and CPVT. Schimpf R; Veltmann C; Wolpert C; Borggrefe M Minerva Cardioangiol; 2010 Dec; 58(6):623-36. PubMed ID: 21135804 [TBL] [Abstract][Full Text] [Related]
33. Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Giustetto C; Di Monte F; Wolpert C; Borggrefe M; Schimpf R; Sbragia P; Leone G; Maury P; Anttonen O; Haissaguerre M; Gaita F Eur Heart J; 2006 Oct; 27(20):2440-7. PubMed ID: 16926178 [TBL] [Abstract][Full Text] [Related]
34. [Early repolarisation with ventricular fibrillation in a young woman]. Ben Ameur Y; Ben Slima H; Joulak A; Sdiri W; Tlili R; Boujnah MR Presse Med; 2013 Apr; 42(4 Pt 1):474-9. PubMed ID: 22959338 [No Abstract] [Full Text] [Related]
35. J wave elevation to monitor quinidine efficacy in early repolarization syndrome. Sacher F; Derval N; Horlitz M; Haïssaguerre M J Electrocardiol; 2014; 47(2):223-5. PubMed ID: 24332747 [TBL] [Abstract][Full Text] [Related]
36. Computational Analysis of the Mode of Action of Disopyramide and Quinidine on hERG-Linked Short QT Syndrome in Human Ventricles. Whittaker DG; Ni H; Benson AP; Hancox JC; Zhang H Front Physiol; 2017; 8():759. PubMed ID: 29085299 [TBL] [Abstract][Full Text] [Related]
37. Modelling the effects of quinidine, disopyramide, and E-4031 on short QT syndrome variant 3 in the human ventricles. Luo C; Wang K; Zhang H Physiol Meas; 2017 Sep; 38(10):1859-1873. PubMed ID: 28812984 [TBL] [Abstract][Full Text] [Related]
38. Emerging therapeutic targets in the short QT syndrome. Hancox JC; Whittaker DG; Du C; Stuart AG; Zhang H Expert Opin Ther Targets; 2018 May; 22(5):439-451. PubMed ID: 29697308 [TBL] [Abstract][Full Text] [Related]